WAYNE, Pa., November 5, 2025 — Leads & Copy — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has announced its new product candidate, QTORIN™ pitavastatin, for disseminated superficial actinic porokeratosis (DSAP) treatment. DSAP is a premalignant disease impacting over 50,000 U.S. patients, with no FDA-approved therapies.
QTORIN™ pitavastatin leverages the company’s patented QTORIN™ platform and aims to inhibit the mevalonate pathway, the causal driver of DSAP. Palvella plans to initiate a Phase 2 trial in the second half of 2026.
The company will host a webcast conference call today, November 5, 2025, at 8:30 a.m. ET, accessible via Palvella’s website.
QTORIN™ rapamycin, Palvella’s lead product candidate, is being developed for the treatment of microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas.
QTORIN™ rapamycin and QTORIN™ pitavastatin are for investigational use only and neither has been approved or cleared by the FDA or by any other regulatory agency for any indication.
Contact Information:
Investors: Wesley H. Kaupinen, Founder and CEO, Palvella Therapeutics, wes.kaupinen@palvellatx.com
Media: Marcy Nanus, Managing Partner, Trilon Advisors LLC, mnanus@trilonadvisors.com
Source: Palvella Therapeutics, Inc.
